- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02390921
The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron (BARIFER)
The Effectiveness of Oral Treatment With Liposomated Iron in Patients With Previous Bariatric Surgery Which Are Currently Receiving Chronic Parentheral Therapy With Iron
Bariatric surgery is the most effective long-term treatment of morbid obesity treatment, so you can maintain weight loss enduringly with improvement or resolution of comorbidity and mortality reduction. All bariatric surgery techniques in postoperative induce a significant reduction in food intake and / or absorption of nutrients and therefore may be associated with a risk of nutritional deficiency, which increases over the years after surgery. One of the nutrients whose absorption is affected significantly is iron, women of childbearing age segment most vulnerable being. A significant percentage of these women require oral supplementation with high doses of iron and often parenteral treatment is needed for digestive intolerance or therapeutic failure.
Hypothesis: The liposome orally administered iron could represent a therapeutic alternative in women of childbearing age, previously undergone bariatric surgery that currently require parenteral iron therapy.
Objectives: To evaluate the tolerability and efficacy of oral iron liposome female patients previously undergone bariatric surgery that currently require parenteral replacement therapy, as well as the impact on quality of life.
Methods: a single center, open, prospective, interventional, in 40 women of childbearing age, previously undergone bariatric surgery, which currently require intravenous iron therapy chronically. Subjects will be divided into 2 parallel groups: 20 cases and 20 controls matched for age, level of Hb, year after surgery and percentage of weight lost.
Relevance: This study will allow us to identify an alternative treatment with oral iron in the case of patients with severe iron deficiency after bariatric surgery, which currently require parenteral iron therapy due to intolerance to current oral products or therapeutic failure. At the same time it could help reduce healthcare costs and improve the quality of life of these patients, who will not have to enter periodically in solitary day hospital for administration of parenteral iron.
Study Overview
Status
Intervention / Treatment
Detailed Description
This project is proposed with the aim of exploring the efficacy and tolerability of liposome orally administered iron in female patients previously undergone bariatric surgery (gastric bypass) currently receiving parenteral iron therapy chronically.
The hypotheses are:
(i) .- A significant percentage of patients undergoing bariatric surgery have iron deficiency and chronic complication. In the investigators series, approximately 100 women require intravenous iron therapy in a chronic (10% of all patients undergoing bariatric surgery to date), significantly increasing costs.
(ii) .- The liposomal form of iron does not depend on gastric pH and increased bioavailability is not dependent on the presence of the digestive dudodeno circuit.
(iii) .- Increased iron absorption and tolerability allow us to remove chronic intravenous iron therapy in the case of these patients. Thus, majoraria quality of life by reducing healthcare costs and avoiding adverse reactions associated with the procedure.
Main objective: To evaluate the tolerability and efficacy of oral iron liposome female patients previously undergone bariatric surgery that currently require parenteral replacement therapy for chronic form.
Secondary objectives:
(i) .- To evaluate the change in the levels of Hb, ferritin, iron, transferrin saturation at 4, 12 weeks of treatment.
(ii) .- Lay the foundation for future study of pharmacokinetics and pharmacodynamics in patients undergoing bariatric surgery.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
In the clinical study will include:
- women who underwent Y-de-Roux gastric by-pass
- over 18 years, premenopausal
- stable weight in the previous 6 months
- currently receiving parenteral iron therapy regularly in solitary day hospital
- which have signed the informed consent
Exclusion Criteria:
- male
- with mobility problems that constrain a marked inactivity
- with associated disease (chronic obstructive pulmonary cardiac cerebral vascular-disease, illness, accident sequel , severe psychiatric or eating disorder
- undergoing different surgical techniques to gastric bypass
- other causes of iron deficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Liosomated iron therapy
Fisiogen Ferro Forte 28mg every day po, during 3 months
|
The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
Other Names:
|
Experimental: Endovenous Iron Therapy
Venofer 300mg endovenously every 3 months
|
The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-inferiority (change in the levels of Hemoglobin)
Time Frame: 3 months
|
To evaluate the change in the levels of Hemoglobin at 4 and 12 weeks of treatment
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andreea Ciudin, Vall d´Hebrón University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR(AG)275/2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liposomated Iron
-
Swiss Federal Institute of TechnologyJomo Kenyatta University of Agriculture and TechnologyCompletedIron-deficiency | Iron Absorption | Ferritin Threshold | Stable Iron IsotopesKenya
-
Iowa State UniversityCompletedIron-deficiency | Bioavailability | Anemia, Iron Deficiency | Absorption; Iron | Serum IronUnited States
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
Children's Hospital Los AngelesWithdrawnAnemia | Iron-deficiency Anemia | Healthy ControlsUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
RDC Clinical Pty LtdNot yet recruiting
-
Universiti Putra MalaysiaActive, not recruiting
-
Nemysis LtdRDC Clinical Pty LtdNot yet recruitingIron-deficiencyAustralia
-
Jessica RiguttoUniversity of Oxford; Jomo Kenyatta University of Agriculture and Technology... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Pediatric ALL | VaccinationKenya, Switzerland
-
The University of Texas Medical Branch, GalvestonTerminatedPregnancy Related | Iron Deficiency Anemia of PregnancyUnited States
Clinical Trials on Fisiogen Ferro Forte
-
Hacettepe UniversityCompletedIron Deficiency AnemiaTurkey
-
Institut für Klinische Krebsforschung IKF GmbH...Completed
-
Allergopharma GmbH & Co. KGCompletedAllergy | Rhinitis | ConjunctivitisGermany
-
IRCCS San Camillo, Venezia, ItalyFondazione Don Carlo Gnocchi OnlusActive, not recruitingRehabilitation | Stroke, Ischemic | Upper Limb InjuryItaly
-
Ain Shams UniversityCompletedHyperactivity | Impulsivity | InattentiveEgypt
-
Hams Hamed AbdelrahmanCompleted
-
University of Medicine and Dentistry of New JerseyAVVAA World Healthcare Products, Inc.TerminatedPsoriasis | Eczema
-
University of IbadanCompletedParkinson DiseaseNigeria
-
Sherief Abd-ElsalamRecruiting
-
Dr. Frank BehrensUniversity Hospital Frankfurt, Department of Anaesthesiology; IRON4U; University...RecruitingIron Deficiency AnemiaGermany